Corporate Presentation

Obesity Petrelintide In Part 1 of the MAD trial, petrelintide was well-tolerated with no serious or severe TEAEs and no withdrawals ZEAL& ZEALAND PHARMA Number of participants (events) Total AEs Mild Moderate TEAEs in Part 1 of the Phase 1b MAD trial with petrelintide Placebo (n=6) Petrelintide 0.6 mg (n=7) Petrelintide 1.2 mg (n=7) 5 (28) 6 (23) 5 (24) 6 (23) 3 (4) 0 7 (29) 7 (29) 1 (2) Severe 0 Serious 0 Metabolism and nutrition disorders 1 (1) Gl disorders 3 (7) 0 0 6 (9) 2 (6) 0 0 6 (8) 5 (9) Nausea occurred in three participants on petrelintide, with one also reporting vomiting; no other participants reported vomiting • No injection-site reactions were reported, and no participants developed anti-drug antibodies Source: Table adapted from Olsen et al. Poster presented at ObesityWeek, October 14-17, 2023, Dallas, TX. AE=adverse event; Gl=gastrointestinal; MAD=multiple ascending dose; TEAE=treatment-emergent adverse event. 17

View entire presentation